Invetx develops protein-based biotherapeutics specifically for dogs and cats, targeting chronic conditions such as pain, allergies, cancer, and diabetes. By providing highly targeted and effective therapies, Invetx enhances the standard of veterinary care while minimizing the need for daily administration by pet owners.
Funding
$60.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NHFounders
Product
Problem
Dogs and cats, like humans, are living longer, leading to increased prevalence of chronic conditions such as pain, allergies, cancer, and diabetes. Current treatments may not be targeted or effective enough, and often require frequent administration, creating a burden for pet owners.
Solution
Invetx, a division of Dechra Pharmaceuticals, develops protein-based biotherapeutics specifically for dogs and cats to address chronic conditions. These biopharmaceuticals aim to provide highly targeted, effective, and safe therapies, elevating the standard of care in veterinary medicine. By focusing on biotherapeutics, Invetx seeks to minimize the need for frequent administration, improving convenience for pet owners and adherence to treatment plans. The company partners with biotechnology companies to leverage their expertise in developing novel veterinary biotherapeutics.
Target Audience
The primary target audience includes veterinarians seeking advanced treatment options for companion animals and pet owners looking for more effective and convenient therapies for their dogs and cats.
Features
- Protein-based therapeutics designed for specific animal diseases
- Focus on chronic conditions such as pain, allergy, cancer and diabetes
- Targeted therapies for improved efficacy and safety
- Reduced administration frequency to ease the burden on pet owners
- Collaboration with biotechnology companies for advanced therapeutic development